

ックダウンによる細胞への影響を検討した結果、正常型 *Huntingtin* 遺伝子は細胞の生存に重要である可能性が示唆された。これにより、RNAi を利用した根本的治療法の開発においては、正常型遺伝子への影響を少なくした RNAi 誘導法、すなわち対立遺伝子特異的 RNAi 誘導法、が有用であると考えられる。本研究は、さらに、その実現を強力にサポートするアレル特異的 RNAi 活性の簡易評価システムを確立させた(特許出願中)。

F. 研究発表

1. 論文発表

- 1) Ohnishi Y., Tokunaga K., Kaneko K., and Hohjoh H. Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles. *J. RNAi Gene silencing*, (in press), 2006.
- 2) Ohnishi Y., Tokunaga K., Hohjoh H. Influence of assembly of siRNA elements into RNA-induced silencing complex (RISC) by fork-siRNA duplex carrying nucleotide mismatches at the 3' - or 5' -end of the sense-stranded siRNA element. *BBRC*, 329: 516-521, 2005
- 3) Tamura Y., Sakasegawa Y., Omi K., Kishida H., Asada T., Kimura H., Tokunaga K., Hachiya N. S., Kaneko K., Hohjoh H. Association study of the chemokine, CXC motif, ligand 1 (CXCL1) gene with sporadic Alzheimer's disease in a Japanese population. *Neurosci. Letters*, 379: 149-151, 2005
- 4) Sago N., Omi K., Tamura Y., Kunugi H., Toyoka T., Tokunaga K., and Hohjoh

H. RNAi induction and activation in mammalian muscle cells where Dicer and eIF2C translation initiation factors are barely expressed. *BBRC*, 319: 50-57, 2004.

- 5) Hohjoh H. Enhancement of RNAi activity by improved siRNA duplexes. *FEBS Letters* 557: 193-198, 2004.
- 6) Omi K., Tokunaga K., and Hohjoh H. Long-lasting RNAi activity in mammalian neurons. *FEBS Letters* 558: 89-95, 2004

2. 総説

- 1) 北條浩彦. RNAi 効果の評価法. *バイオテクノロジー ジャーナル*, 6: 51-57, 2006.
- 2) 小見和也 & 北條浩彦. 神経細胞の RNAi と応用. *医学のあゆみ*, 208: 659-663, 2004.
- 3) 北條浩彦. RNAi-その基礎と応用、はじめに. *医学のあゆみ*, 208: 647-648, 2004.
- 4) 北條浩彦. 哺乳類細胞での RNA 干渉. *バイオインダストリー*, 21: 44-51, 2004.

3. 学会発表

(国際学会)

- 1) Ohnishi Y., Tokunaga K., Kaneko K., and Hohjoh H. (2005) "Evaluation system for siRNA duplexes conferring allele-specific gene silencing." 55th Annual Meeting of the American Society of Human Genetics, Salt Lake City, Utah, USA.
- 2) Kawashima M., Tamiya G., Hohjoh H., Juji T., Ebisawa T., Honda Y., Inoko H., Tokunaga K. (2005) "A new resistant gene candidate for human narcolepsy identified by a genome-wide

association study” 55th Annual Meeting of the American Society of Human Genetics, Salt Lake City, Utah, USA.

- 3) Ohnishi Y., Omi K., Tamura Y., Tokunaga K., Kaneko K., and Hohjoh H. (2005) “Evaluation system for siRNA duplexes conferring allele-specific gene silencing.” Diverse role RNA in gene regulation, Keystone Symposia, Breckenridge, Colorado, USA.
- 4) Omi K., Tokunaga K., and Hohjoh H. (2004) “RNAi induction in mammalian neurons and muscle cells.” 54th Annual Meeting of the American Society of Human Genetics, Toronto, Ontario, CANADA
- 5) Tamura Y., Kunugi H., Kanako K., and Hohjoh H. (2004) “Analyses of epigenetic DNA methylation in the human genome” 54th Annual Meeting of the American Society of Human Genetics, Toronto, Ontario, CANADA.
- 6) Kawashima M., Ikuta T., Tamiya G., Hohjoh H., Juji T., Honda Y., Inoko H, and Tokunaga K. (2004) “Fine mapping of candidate regions for human narcolepsy with high density markers.” 54th Annual Meeting of the American Society of Human Genetics, Toronto, Ontario, CANADA.

(国内学会)

- 1) 田村美子、功刀浩、金子清俊、北條浩彦. (2005) 「ヒト RELN 遺伝子の DNA メチル化と遺伝子発現レベルの解析」第 28 回日本分子生物学会、福岡.
- 2) 大西悠亮、徳永勝士、徳永勝士、金子清俊、北條浩彦. (2005) 「対立遺伝子特異的

RNAi 効果をヘテロ接合体下で評価するアッセイ系の確立」第 28 回日本分子生物学会、福岡.

- 3) 山本真央、高須美和、徳永勝士、数藤由美子、平井百樹、北條浩彦.、功刀浩、上野美華子、南光進一郎. (2005) 「均衡型染色体転座部位における双極性障害疾患感受性遺伝子探索」第 28 回日本分子生物学会、福岡.
- 4) 小見和也、徳永勝士、北條浩彦. (2004) 「RNAi による遺伝子発現ノックダウンを用いた神経疾患関連遺伝子の機能解析」第 27 回日本分子生物学会、神戸.
- 5) 大西悠亮、小見和也、田村美子、徳永勝士、金子清俊、北條浩彦. (2004) 「対立遺伝子特異的 RNAi 効果の簡易評価システム」第 27 回日本分子生物学会、神戸.
- 6) 田村美子、功刀浩、金子清俊、北條浩彦. (2004) 「メチル化によるエピジェネティックなヒトゲノム修飾に関する研究」第 27 回日本分子生物学会、神戸.
- 7) 小見和也、左合典子、豊岡照彦、徳永勝士、北條浩彦. (2004) 「哺乳動物細胞での RNAi 効果の持続性に関する研究」第 49 回日本人類遺伝学会、東京.
- 8) 川嶋実苗、生田智樹、田宮元、北條浩彦.、十字猛夫、本多裕、猪子英俊、徳永勝士. (2004) 「ゲノムワイド関連分析より検出したヒトナルコレプシー候補領域 fine mapping」第 49 回日本人類遺伝学会、東京
- 9) 小見和也、徳永勝士、北條浩彦. (2003) “Long-term effect of RNA interference (RNAi) on mammalian neurons” 第 26 回日本分子生物学会、神戸.
- 10) 左合典子、小見和也、田村美子、功刀浩、豊岡照彦、徳永勝士、北條浩彦. (2003)

「マウス筋芽細胞由来株 C2C12 細胞における RNA interference」第 26 回日本分子生物学会、神戸.

G. 知的財産権の出願・登録状況

1) PCT 出願

優先権主張出願日・番号:

平成 15 年 8 月 18 日・特願 2003-294504

平成 15 年 12 月 24 日・特願 2003-427970

PCT 出願日・番号:平成 16 年 8 月 18 日

PCT/JP2004/011822

PCT 公開日・番号:平成 17 年 2 月 24 日

WO 2005/017154

発明者: 北條浩彦

発明の名称:「改良された siRNA 分子およびこれを用いた遺伝子発現の抑制法」

出願人:財団法人ヒューマンサイエンス振興財団

2) 特許出願

特許出願番号: 2005-116177

発明者:北條浩彦

発明の名称:「対立遺伝子に対する特異的 RNAi の評価方法」

出願人:財団法人ヒューマンサイエンス振興財団とプロメガ株式会社との共同出願

出願日:平成 17 年 4 月 13 日

II 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の 編集者名	書 籍 名	出版社名	出 版 地	出 版 年	ページ

雑誌

平成15年度

発 表 者 氏 名	論 文 タ イ ト ル 名	発 表 誌 名	巻 号	ペ ー ジ	出 版 年
Nishikawa, K., Li, H., Kawamura, R., Osaka, H., Wang, Y.L., Hara, H., Hirokawa, T., Manago, M., Amano, J, Noda, M., Aoki, S. and Wada, K.	Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants.	Biochem. Biophys. Res. Comm.	304	176-183	2003
Osaka, H., Wang, Y.L., Takada, K., Takizawa, S., Setsuie, R., Li, H., Sato, Y., Nishikawa, K., Sun, Y.J., Sakurai, M., Harada, T., Hara, Y., Kimura, I., Chiba, S., Namikawa, K., Kiyama, H., Noda, M., Aoki, S. and Wada, K.	Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neurons.	Hum. Mol. Genet.	12	1945-1958	2003
Harada, T., Harada, C., Wang, Y.L., Osaka, H., Amanai, K., Tanaka, K., Takizawa, K., Setsuie, R., Sakurai, M., Sato, Y., Noda, M. and Wada, K.	Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury <i>in vivo</i> .	Am. J. Pathol.	164	59-64	2004
Castegna, A., Thongboonkerd, V., Klein, J., Lynn, B., Wang, Y.L., Osaka, H., Wada, K. and Butterfield, D.A.	Proteomic Analysis of the Brain Proteins in the Gracile Axonal Dystrophy (gad) Mouse, a Syndrome That Emanates from Dysfunctional Ubitquitin Carboxyl-Terminal Hydrolase L-1, Reveals Oxidation of Key Proteins.	J. Neurochem.	88	1540-1546	2004
Liu, W., Goto, J., Wang, Y.L., Murata, M., Wada, K. and Kanazawa, I.	Specific inhibition of Huntington's disease gene expression by siRNAs in cultured cells.	Proc. J. Acad.	79, SerB	293-298	2003
Hohjoh H.	Enhancement of RNAi activity by improved siRNA duplexes.	FEBS Lett.	557	193-198	2004
Omi K., Tokunaga K., and Hohjoh H.	Long-lasting RNAi activity in mammalian neurons.	FEBS Lett.	558	89-95	2004

平成16年度

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Bonin, M., Poths, S., Osaka, H., Wang, Y.L., Wada, K. and Riess, O.	Microarray expression analysis of gad mice implicates involvement of Parkinson's disease associated UCH-L1 in multiple metabolic pathways.	Mol. Brain Res.	126	88-97	2004
Wang, Y.L., Takeda, A., Osaka, H., Hara, Y., Furuta, A., Setsuie, R., Sun, Y.J., Kwon, J., Sato, Y., Sakurai, M., Noda, M., Yoshikawa, Y. and Wada, K.	Accumulation of b- and g-synucleins in the ubiquitin C-terminal hydrolase L1 deficient gad mouse.	Brain Res.	1019	1-9	2004
Kwon, J., Wang, Y.L., Setsuie, R., Sekiguchi, S., Sato, Y., Sakurai, M., Noda, M., Aoki, S., Yoshikawa, Y. and Wada, K.	Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testes.	Am. J. Pathol.	165	1367-1374	2004
Mi, W., Beirowski, B., Gillingwater, T.H., Adalbert, R., Wagner, D., Grumme, D., Osaka, H., Conforti, L., Arnhold, S., Addicks, K., Wada, K., Ribchester, R.R. and Coleman, M.P.	The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice.	Brain	128	405-416	2005
Manago, Y., Kanahori, Y., Shimada, A., Sato, A., Amano, T., Sato, Y., Setsuie, R., Sakurai, M., Aoki, S., Wang, Y.L., Osaka, H., Wada, K. and Noda, M.	Potentiation of ATP-induced currents due to the activation of P2X receptors by ubiquitin carboxy-terminal hydrolase L1.	J. Neurochem.	92	1061-1072	2005
Sago N., Omi K., Tamura Y., Kunugi H., Toyo-ka T., Tokunaga K., and Hohjoh H.	RNAi induction and activation in mammalian muscle cells where Dicer and eIF2C translation initiation factors are barely expressed.	BBRC	319	50-57	2004
Ohnishi Y., Tokunaga K., and Hohjoh H.	Influence of assembly of siRNA elements into RNA-induced silencing complex by fork-siRNA duplex carrying nucleotide mismatches at the 3'- or 5'-end of the sense-stranded siRNA element.	BBRC	329	516-521	2005

平成17年度

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kwon, J., Mochida, K., Wang, Y.L., Sekiguchi, S., Sankai, T., Aoki, S., Ogura A., Yoshikawa, Y. and Wada, K.	Ubiquitin C-terminal hydrolase L1 is essential for the early apoptotic wave of germinal cells and for sperm quality control during spermatogenesis.	Biol. Reprod.	73	29-35	2005
Wang, Y.L., Liu, W., Wada, E., Murata, M., Wada, K., Kanazawa, I.	Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.	Neurosci. Res.	53	241-249	2005
Wang, Y.L., Liu, W., Sun, Y.J., Kwon, J., Setsuie, R., Osaka, H., Noda, M., Aoki, S., Yoshikawa, Y., Wada, K.	Overexpression of ubiquitin carboxyl-terminal hydrolase L1 arrests spermatogenesis in transgenic mice.	Mol. Reprod. Dev.	73,	40-49	2006
Naito S, Mochizuki H, Yasuda T, Mizuno Y, Furusaka M, Ikeda S, Adachi T, Shimizu HM, Suzuki J, Fujiwara S, Okada T, Nishikawa K, Aoki S, Wada K.	Characterization of multimetric variants of ubiquitin carboxyl-terminal hydrolase L1 in water by small-angle neutron scattering.	Biochem Biophys Res Commun.	339	717-725	2006
Sakurai, M., Ayukawa, K., Setsuie, R., Nishikawa, K., Hara, Y., Ohashi, H., Nishimoto, M., Abe, T., Kudo, Y., Sekiguchi, M., Sato, Y, Aoki, S., Noda, M., Wada, K.	Ubiquitin C-terminal hydrolase L1 regulates the morphology of neural progenitor cells and modulates their differentiation.	J. Cell Sci.	119(Pt1)	162-171	2006
Kwon, J., Sekiguchi, S., Wang, Y.L., Setsuie, R., Yoshikawa, Y. and Wada, K.	The region-specific functions of two ubiquitin C-terminal hydrolase isozymes along the epididymis.	Exp. Anim.	55(1),	35-43	2006
Tamura Y., Sakasegawa Y., Omi K., Kishida H., Asada T., Kimura H., Tokunaga K., Hachiya N.S., Kaneko K., and Hohjoh H.	Association study of the chemokine, CXC motif, ligand 1 (CXCL1) gene with sporadic Alzheimer's disease in a Japanese population.	Neurosci Lett.	379	149-151	2005
Ohnishi Y., Tokunaga K., Kaneko K., and Hohjoh H.	Assessment of allele-specific gene silencing by RNA interference with mutant and wild-type reporter alleles.	J. RNAi Gene silencing		in press	2006
北條浩彦	RNAi 効果の評価法～本当に RNAi が起こっているのか？	バイオテクノロジージャーナル	1-2	51-57	2006

III. 研究成果の刊行物・印刷



ACADEMIC
PRESS

Available online at www.sciencedirect.com

SCIENCE @ DIRECT®

Biochemical and Biophysical Research Communications 304 (2003) 176–183

BBRC

www.elsevier.com/locate/ybbrc

Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants

Kaori Nishikawa,^{a,b} Hang Li,^a Ryoichi Kawamura,^c Hitoshi Osaka,^{a,d} Yu-Lai Wang,^a
Yoko Hara,^{a,b} Takatsugu Hirokawa,^e Yoshimasa Manago,^f Taiju Amano,^f Mami Noda,^f
Shunsuke Aoki,^a and Keiji Wada^{a,*}

^a Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry,
4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, Japan

^b Japan Science and Technology Corporation (JST), Kawaguchi, Saitama 332-0012, Japan

^c Blood Products Research Department, The Chemo-Sero-Therapeutic Research Institute, Kumamoto 869-1298, Japan

^d Precursory Research for Embryonic Science and Technology (PRESTO), JST, Kawaguchi, Saitama 332-0012, Japan

^e Computational Biology Research Center (CBRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo 135-0064, Japan

^f Laboratory of Pathophysiology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan

Received 14 March 2003

Abstract

Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is a neuron-specific ubiquitin recycling enzyme. A mutation at residue 93 and polymorphism at residue 18 within human UCH-L1 are linked to familial Parkinson's disease and a decreased Parkinson's disease risk, respectively. Thus, we constructed recombinant human UCH-L1 variants and examined their structure (using circular dichroism) and hydrolase activities. We confirmed that an I93M substitution results in a decrease in k_{cat} (45.6%) coincident with an alteration in α -helical content. These changes may contribute to the pathogenesis of Parkinson's disease. In contrast, an S18Y substitution results in an increase in k_{cat} (112.6%) without altering the circular dichroistic spectrum. These data suggest that UCH-L1 hydrolase activity may be inversely correlated with Parkinson's disease risk and that the hydrolase activity is protective against the disease. Furthermore, we found that oxidation of UCH-L1 by 4-hydroxynonenal, a candidate for endogenous mediator of oxidative stress-induced neuronal cell death, results in a loss of hydrolase activity. Taken together, these results suggest that further studies of altered UCH-L1 hydrolase function may provide new insights into a possible common pathogenic mechanism between familial and sporadic Parkinson's disease.

© 2003 Elsevier Science (USA). All rights reserved.

Keywords: Ubiquitin; Proteasome; UCH-L1; Parkinsonism; Oxidative stress; 4-Hydroxynonenal

The ubiquitin–proteasome system is an evolutionarily conserved and energy-dependent proteolytic pathway. In addition to the elimination of misfolded and damaged toxic proteins produced in response to various cellular stresses, this pathway is responsible for turnover of various classes of short-lived proteins that control cell-cycle progression, specific gene transcription, membrane protein traffic, and intracellular signaling [1–4].

Ubiquitination of proteins is mediated by specific enzymes (E1, E2, and E3), and polyubiquitinated proteins are translocated to the proteasome and subsequently proteolytically degraded [3]. Conversely, deubiquitination is thought to be essential for the negative regulation of proteolysis and for recycling of ubiquitin from polyubiquitin chains [5].

Deubiquitinating enzymes consist of at least two families: the UBP (ubiquitin-specific processing protease) family [6–9] and the UCH family [7,8]. UBPs are thought to disassemble polyubiquitin chains whereas

* Corresponding author. Fax: +81-42-346-1745.

E-mail address: wada@ncnp.go.jp (K. Wada).

UCHs hydrolyze only small C-terminal ubiquitin adducts [8–10]. This restricted substrate specificity led to the proposal that UCHs function in ubiquitin recycling rather than in deubiquitination [11,12]. To date, four isoforms of UCH, L1–L4, have been identified in mammals [13–15].

Of the four UCH isoforms, UCH-L1 is neuron-specific [16,17]. Mutant mice with an intragenic deletion of the *UCH-L1* gene display neuron subtype-specific phenotypes and severe neurodegenerative disorders including gracile axonal dystrophy [18]. Previous studies of *UCH-L1*-associated human neurodegenerative diseases revealed single amino acid changes within UCH-L1 in some patients with Parkinson's disease (PD). An I93M missense mutation was identified in a German family affected by PD, and the partial loss of UCH-L1 hydrolase activity in this mutant may contribute to the disease [19]. Furthermore, an S18Y polymorphism encoded in exon 3 of human *UCH-L1* may be associated with decreased risk of PD in Caucasian, German, and Japanese populations [20–24] although no such association has been identified in other populations [25–28]. Recently, a novel enzymatic activity of UCH-L1 was discovered that affects the degradation of α -synuclein, a core component of Lewy bodies. The study demonstrated that the UCH-L1 dimer exhibits an ATP-independent ubiquitin ligase activity that inhibits the degradation of ubiquitinated α -synuclein (ubiquitinated at Lys 63) [29]. Furthermore, S18Y UCH-L1 ligase activity is lower than that of the wild-type enzyme, suggesting a possible link between the ligase activity and lowered risk of PD [29].

Although the I93M mutation and S18Y polymorphism of UCH-L1 could affect a single factor in the etiology of PD, common functional changes between the I93M and S18Y mutants of UCH-L1 have not been reported. In the present study, we reveal that UCH-L1 hydrolase activity is altered in both the I93M and S18Y UCH-L1 variants, suggesting that the pathogenesis of PD in both cases may have a common origin. We further demonstrate that UCH-L1 hydrolase activity is decreased by treatment with 4-hydroxynonenal (HNE), a candidate for endogenous mediator of oxidative stress-induced neuronal cell death, which is associated with sporadic PD. Thus, the hydrolase activity may also be involved in the pathogenesis of sporadic PD. Moreover, we also reveal that I93M UCH-L1 exhibits altered α -helical content relative to wild-type UCH-L1.

Materials and methods

Cloning of human UCH-L1. Human *UCH-L1* cDNA (GenBank Accession No. BC006305) was amplified by PCR using a human brain cDNA pool (Stratagene, La Jolla, CA) as template with the following primer sets: forward primer, 5'-GGGGCTCGAGCCGCGAAGATGCAGCTCAAGCCGATGGAGATCAACCCGAGATGCTGA-3' (5'-GGGG-*Xho*I-CCGCGAAG-Met¹-Gln-Leu-Lys-Pro-Met-Glu-Ile-

Asn-Pro-Glu-Met-Leu¹³-3'), and reverse primer, 5'-GGGGGCGG CCGCTTAGGCTGCCTTGCAGAGAGCCA-3' (3'-Ala²²⁶-Leu-Cys-Lys-Ala-Ala²³³-stop-*Not*I-GGGG-5'). Following an initial 3 min denaturation at 95 °C, the sample was amplified by 30 cycles of denaturation at 95 °C for 10 s, annealing at 53 °C for 20 s, and extension at 72 °C for 30 s. The amplified fragment was digested with *Xho*I and *Not*I and subcloned into the *Xho*I and *Not*I sites of pCI-neo (Promega, Madison, WI). Accuracy of the inserted nucleotide sequence was confirmed by sequence analysis.

Construction of bacterial expression plasmids for human UCH-L1 variants. Mutant cDNAs encoding human UCH-L1 containing either the I93M, S18Y, or C90S substitution were obtained using the Quik-Change site-directed mutagenesis kit (Stratagene) with the following mutagenesis oligonucleotides: 5'-GAATTCCTGTGGCACAATGGACTTATTCACGCAG-3' and 5'-CTGCGTGAATAAGTCCCATTGTGCCACAGGAATTC-3' for I93M; 5'-GAACAAAGTGTGTCCCGGCTGGGGTTCGC-3' and 5'-GCGACCCCCAGCCGGGACAGCACTTTGTTC-3' for S18Y; and 5'-CCATTGGGAATTCCTCTGGCACAATCGGAC-3' and 5'-GTCCGATTGTGCCACAGGAATCCCAATGG-3' for C90S. Each single-nucleotide mutation in the resulting plasmids was confirmed by sequencing. Bacterial expression plasmids containing either 6HN-tagged human UCH-L1, I93M, S18Y, or C90S were constructed using a tetracycline-inducible expression system. *Xho*I-*Not*I cDNA fragments of the pCI-neo human UCH-L1 and mutant were digested, and then the DNA fragments were ligated between the *Sal*I and *Not*I sites in pPROtetE233 (Clontech, Palo Alto, CA) to generate pPROtetE233 6HN-tagged human UCH-L1, I93M, S18Y, and C90S vectors. The veracity of these expression plasmids was confirmed by sequencing.

Preparation of recombinant proteins. The pPROtetE233 6HN-tagged human UCH-L1, I93M, S18Y, and C90S vectors were transformed into *Escherichia coli* DH5 α PRO. Purification of the recombinant proteins was performed using Co²⁺-Sephrose (TALON purification kit, Clontech) according to the manufacturer's instructions.

Protein concentrations were determined using the BCA protein assay reagent (Pierce). Purified proteins were resolved by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) under reducing conditions and visualized by Coomassie brilliant blue R-250 to confirm purity.

In vitro assay for human UCH-L1 activity. The hydrolase assay was performed as described in [30] with slight modifications. The assay for human UCH-L1 was carried out using a 96-well black assay plate at room temperature. Purified enzymes and the fluorogenic substrate ubiquitin-7-amino-4-methylcoumarin (Ub-AMC) (Boston Biochem, Cambridge, MA) were used to determine steady state kinetic parameters. The final enzyme concentration was 4.3 nM for UCH-L1, I93M, and S18Y mutants, and 5 μ M for C90S. Before adding the substrate, the enzyme was incubated in assay buffer (20 mM HEPES, 0.5 mM EDTA, pH 7.8, containing 0.1 mg/ml ovalbumin, and 5 mM dithiothreitol) for 2 h to prevent oxidation of thiol groups. The substrate was diluted with assay buffer to a final concentration of 17.6–900 nM and a 50- μ l aliquot was added to each well on the 96-well plate. The assay was initiated by the addition of 50 μ l of stock enzyme solution. Fluorescence ($\lambda_{\text{ex}} = 355$ nm, $\lambda_{\text{em}} = 460$ nm) of AMC was monitored continuously using a Wallac 1420 multi-label counter (Perkin-Elmer, Turku, Finland), and the concentration of AMC was determined using standard curves of fully digested substrates. Initial velocity data were used to determine K_m and k_{cat} values from nonlinear fits of the Michaelis-Menten equation.

Circular dichroism. Circular dichroism (CD) measurements were performed as described in [31]. Purified recombinant human UCH-L1 and mutants were adjusted to a concentration of 0.1 mg/ml and dialyzed against 20 mM sodium phosphate buffer (pH 8.0). Far UV CD spectra (195–250 nm) were recorded in a 1-mm quartz cuvette on a Jasco J-820 spectropolarimeter (Jasco, Tokyo, Japan) equipped with a temperature controller by scanning at the rate of 50 nm/min at 20 °C. For all spectra, six scans were averaged. All CD spectra were corrected by background

subtraction for the spectrum obtained with buffer alone and smoothed. The observed ellipticity was normalized to units of degrees-cm²/dmol. The spectra were analyzed for percent secondary structural elements by a computer program based on an algorithm that compares experimental spectra with those of known proteins [32]. Student's *t* test was used to compare the significance of the differences between data.

Modification of human UCH-L1. Recombinant 6HN-tagged human UCH-L1 proteins (0.3 mg/ml) were incubated with various concentrations (0–1.0 mM) of HNE (Calbiochem, San Diego, CA) in 60 μ l of 50 mM sodium phosphate buffer (pH 7.2) for 2 h at 37°C, as described in [33]. HNE-modification of UCH-L1 was monitored by SDS-PAGE and immunoblotting. Modified proteins (500 ng) were dissolved in the SDS-PAGE sample buffer and separated by 10–20% gradient SDS-PAGE prior to transfer to a PVDF membrane (Bio-Rad, Hercules, CA). After blocking with 5% nonfat dried milk and 3% goat serum in PBS, blots were probed with rabbit anti-HNE Michael Adducts antibody (1:2000, Calbiochem). Following washes, proteins reacting with a secondary antibody, HRP-conjugated goat anti-rabbit IgG (1:2000, Dako), were visualized using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce).

Assay of residual hydrolase activity. HNE modified sample (55 μ l) was applied to a MicroSpin G-25 Column (Amersham Pharmacia Biotech) to separate protein-bound HNE from free HNE. Recovery of the protein was established by SDS-PAGE and staining with Coomassie brilliant blue R-250. Residual activity of the modified enzyme was determined as described above. Initial velocity data were used to determine the values for relative activity.

Results

Purification and characterization of recombinant human UCH-L1 proteins

To obtain wild-type UCH-L1 and the variants I93M and S18Y associated with Parkinson's disease (Fig. 1A), N-terminal 6HN-tagged recombinant proteins were expressed in *E. coli* and purified by metal chelate affinity




Fig. 1. Characterization and analysis of purified recombinant 6HN-tagged human UCH-L1s. (A) Schematic representation of 6HN-tagged human UCH-L1 wild-type (WT) and mutants I93M, S18Y, and C90S. The numbers indicate the amino acid residues of the N- and C-termini of UCH-L1 (open reading frame). The positions of the point mutations are indicated. The N-terminal 6HN-tag is shown in white. (B) Visualization of recombinant 6HN-tagged human UCH-L1s by SDS-PAGE under reducing conditions and Coomassie staining. One microgram of each sample was subjected to analysis. The arrow indicates the 28.9-kDa 6HN-tagged human UCH-L1 bands. M_r , molecular weight markers (kDa). (C) Kinetics of WT UCH-L1-catalyzed hydrolysis of Ub-AMC. Fluorescence intensity ($\lambda_{ex} = 355$ nm, $\lambda_{em} = 460$ nm) is indicated as a function of time. Enzyme concentration was 4.3 nM and substrate concentrations are indicated on the right. (D) Kinetics of C90S UCH-L1-catalyzed hydrolysis of Ub-AMC. Enzyme concentration was 4.3 μ M and substrate concentration was 900 nM. (E) Effect of Ub-AMC concentration on the initial velocity of hydrolysis for WT UCH-L1 and variants. Activity measurements were performed using 4.3 nM 6HN-tagged human UCH-L1 or variant. Closed circle, WT; open circle, S18Y; closed triangle, I93M. Each value represents the mean \pm SE of three independent experiments. Error bars are not shown if the error is smaller than the symbol.

chromatography. Coomassie staining of the purified proteins following SDS–PAGE showed a single 28.9-kDa band for each of the 6HN-tagged proteins (Fig. 1B) in good agreement with the theoretical 27.8-kDa molecular mass of the 6HN-tagged UCH-L1. The expression levels for the wild-type and variant UCH-L1 proteins were equivalent. As a negative control, we prepared a recombinant human C90S UCH-L1 in which serine is substituted within the active center triad [11] (Fig. 1A). The purified C90S UCH-L1 exhibited no hydrolase activity even at a very high concentration of 5 μ M (Table 1; Fig. 1D), supporting the SDS–PAGE result (Fig. 1B) that there were no contaminant proteins with hydrolase activity in our recombinant protein preparations.

Kinetics of Ub-AMC hydrolysis by wild-type and variant UCH-L1s

UCH-L1 is a ubiquitin hydrolase that specifically cleaves small adducts of C-terminally modified ubiquitin (ubiquitin^{1–72}-Leu⁷³-Arg⁷⁴-Gly⁷⁵-Gly⁷⁶-X, where X can be any leaving group such as an amine, thiol group, small peptide, and polypeptide) [12]. To determine the enzymatic activities of recombinant human UCH-L1 and variants, we performed a general deubiquitinating assay using Ub-AMC as a substrate. Ub-AMC is efficiently hydrolyzed by UCH-L3 to liberate the highly fluorescent AMC moiety [30]. The hydrolase activity of wild-type UCH-L1 was compared with those of the parkinsonism-associated variants. Using varying concentrations of Ub-AMC, a Michaelis–Menten saturation curve was generated to determine the kinetics of catalysis for wild-type human UCH-L1 (Fig. 1C). Catalysis was saturated at 600–900 nM Ub-AMC (Figs. 1C and E). Next, steady-state kinetic parameters for each UCH-L1 mutant were determined using 4.3 nM wild-type and variant UCH-L1 and varying concentrations of Ub-AMC. The initial velocities were fit to the Michaelis–Menten equation to provide nonlinear least-squares parameters (Fig. 1E; Table 1). The k_{cat} for the wild-type

UCH-L1 was $0.174 \pm 0.0057 \text{ s}^{-1}$, while k_{cat} for the I93M and S18Y variants was $0.0794 \pm 0.0034 \text{ s}^{-1}$ and $0.196 \pm 0.0028 \text{ s}^{-1}$, respectively (wild-type vs I93M, $p < 0.01$; wild-type vs S18Y, $p < 0.05$). The hydrolase activity of the I93M mutant was 45.6% of that of the wild-type UCH-L1. In contrast, the activity of the S18Y UCH-L1 variant was 1.13-fold higher than that of wild-type. The mutant and wild-type proteins exhibited similar K_m values, $K_m^{\text{wt}} = (122 \pm 10) \times 10^{-9} \text{ M}$, $K_m^{\text{I93M}} = (110 \pm 14) \times 10^{-9} \text{ M}$, and $K_m^{\text{S18Y}} = (136 \pm 1.7) \times 10^{-9} \text{ M}$, indicating that the mutant proteins showed similar affinity for Ub-AMC. In another study using recombinant UCH-L1, Liu et al. [29] reported that the S18Y and wild-type proteins exhibit equivalent hydrolase activities. The disagreement between their results and ours may be due to differences in protein preparations and/or hydrolase assay methods. We confirmed that the difference in the hydrolase activities of wild-type and S18Y UCH-L1s was statistically significant using independent protein preparations, and therefore we are confident that the hydrolase activity of S18Y UCH-L1 is higher than that of wild-type UCH-L1. The increased hydrolase activity appears to be a direct result of the S18Y mutation since the S18Y and wild-type UCH-L1 preparations contain no contaminant proteins or activities (Figs. 1B–D). Also, both proteins exhibit the same CD spectra (Fig. 2A). Significantly, the increased hydrolase activity of S18Y UCH-L1 was recently confirmed by another group [34].

CD analysis of secondary structure in wild-type and variant human UCH-L1s

To address whether the observed differences in hydrolase activities of the variant UCH-L1s reflect altered secondary structure, we utilized CD spectroscopy to estimate secondary structure in the recombinant proteins (Fig. 2A). Human UCH-L1 and the variant proteins exhibited spectra with distinct minima at 208 and 222 nm, characteristic of high α -helical content (Fig. 2A). The ratios of α -helix, β -sheet, and other secondary structural features in these proteins were estimated from mean residue ellipticity data and are presented graphically in Fig. 2B. Relative to wild-type, the I93M mutant displayed slightly lower ellipticity over the range 195–200 nm, indicating decreased α -helical content (Fig. 2A, left). As a control, we prepared a recombinant double mutant UCH-L1 containing both the S18Y and I93M substitutions. The CD spectrum of the S18Y–I93M double mutant over 195–200 nm was similar to that of I93M (Fig. 2A, right), indicating that the amino acid substitution at position 93 is responsible for the decreased α -helical content. In contrast, the CD spectrum of the S18Y variant exhibited no difference compared to that of the wild-type protein.

Table 1
Kinetic parameters for hydrolysis of Ub-AMC by human UCH-L1s

Enzyme	k_{cat} (s^{-1})	K_m (nM)
UCH-L1 (wild-type)	0.174 ± 0.0057	122 ± 10
I93M	$0.0794^{**} \pm 0.0034$	110 ± 14
S18Y	$0.196^{*} \pm 0.0028$	136 ± 1.7
C90S ^a	N.D. ^b	N.D. ^b

Each value represents the means \pm SE from three independent sets of experiments. * $p < 0.05$, ** $p < 0.01$ compared with values for UCH-L1 (wild-type) by t test.

^aNo hydrolyzed products were observed after 1 h with 5 μ M enzyme.

^bN.D., not detectable.




Fig. 2. CD spectra and secondary structural content of 6HN-tagged human UCH-L1s. (A) CD spectra (mean residue ellipticity) for recombinant proteins (0.1 mg/ml) in 50 mM sodium phosphate buffer. Wild-type UCH-L1 (WT) is shown in blue, I93M in green, S18Y in red, and S18Y-I93M in violet. Six scans were averaged for all spectra. Arrowheads indicate the differences of CD spectra. (B) Secondary structural content of recombinant human 6HN-tagged UCH-L1s. Each value represents the mean \pm SE of six data sets. p value (t test) for the WT vs other proteins: **, < 0.01 .

Modification and inactivation of UCH-L1 hydrolase activity by HNE

UCH-L1 belongs to a papain-like cysteine protease family [4,35] with conserved Cys and His residues within the active site. Certain cysteine proteases are known to be targets of cellular oxidative stress [36], and several lines of evidence implicate this phenomenon in sporadic PD [46]. One of the endogenous factors that is toxic to neurons during oxidative stress is HNE, an aldehyde product of fatty acid peroxidation. HNE can induce neuronal death [37,38] and is thought to form covalent cross-links with proteins via Michael addition to Cys, His, and Lys residues, thus altering the function of cysteine proteases [36]. HNE-modified proteins have been detected in nigral neurons and Lewy bodies in sporadic PD [39,40]. We examined whether HNE directly modifies/inactivates UCH-L1 in vitro. Past studies

determined that HNE is produced in micromolar concentrations in response to certain oxidative stresses [41–43]. We utilized micromolar concentrations of HNE and 10 μ M UCH-L1 for our experiments (UCH-L1 is an abundant protein, comprising 1–2% of soluble brain protein) [17,44]. Physiological concentrations of HNE (10–100 μ M) were sufficient to covalently modify UCH-L1 and reduce hydrolase activity by 40–80% (Figs. 3A and B). Covalent modification also occurred at a lower




Fig. 3. Effect of HNE and NAC on UCH-L1 hydrolase activity. (A) Modification of wild-type UCH-L1 with HNE was visualized by immunoblot analysis with HNE adduct-specific antibody (top panel). HNE-modified UCH-L1 from the same sample was resolved by SDS-PAGE and stained with Coomassie brilliant blue (bottom panel). (B) Inactivation of UCH-L1 hydrolase activity by HNE and rescue with NAC (top panel). The residual activities of HNE-modified UCH-L1 prepared from the same sample shown in (A) were measured by hydrolase assay. Each value represents the mean \pm SE of four experiments. The HNE-modified UCH-L1 proteins were separated from free HNE, resolved by SDS-PAGE, and stained with Coomassie brilliant blue (bottom panel).

concentration of UCH-L1 (1.25 μ M; data not shown). Moreover, excess *N*-acetyl-L-cysteine (NAC; as a competitive cysteine analogue) prevented both HNE modification (Fig. 3A) and the decrease in hydrolase activity, thus confirming that human UCH-L1 was modified with HNE (Fig. 3B).

Discussion

We analyzed the hydrolase activities of parkinsonism-associated UCH-L1 variants, I93M and S18Y. The I93M mutation causes a decrease in the hydrolase activity in agreement with a previous report [19]. Furthermore, the S18Y variant exhibits slightly higher hydrolase activity than the wild-type enzyme. We also examined the structural features of the UCH-L1 variants by CD spectroscopy. The wild-type and S18Y UCH-L1 proteins elicit essentially identical CD spectra while the I93M mutant exhibits a decrease in α -helical content. Finally, we found that UCH-L1 modification by HNE decreases its hydrolase activity.

The I93M UCH-L1 mutant exhibits reduced hydrolase activity (~55% of wild-type), and this mutant displays 80% penetrance in a German family carrying the allele [19]. Conversely, genetic-epidemiological studies demonstrated that carriers of the S18Y UCH-L1 polymorphism that causes increased hydrolase activity show a decreased risk of sporadic PD. Furthermore, the risk of PD is also dependent on the S18Y allele dosage in that homozygotes of this allele are at lower relative risk (0.31) than heterozygotes (relative risk between 0.55 and 0.81) [21,24,25]. Thus, the PD risk appears to correlate inversely with the hydrolase activity of the UCH-L1 variants associated with PD (Table 2), suggesting that increased hydrolase activity may confer protection against the development of PD while decreased activity may be involved in PD pathogenesis.

Another study using recombinant UCH-L1 proteins demonstrated that UCH-L1 has dual enzymatic activity, both as a ubiquitin hydrolase and an ATP-independent ubiquitin ligase for α -synuclein [29]. It was also shown that the ligase activity of S18Y UCH-L1 is decreased relative to that of the wild-type UCH-L1. These results suggest that the ligase activity, in addition to the hydrolase activity, is involved in PD etiology. Our results demonstrate that the I93M mutation both impairs hy-

drolase activity and perturbs the structure in the protein. Given that UCH-L1 is an abundant protein (1–2% of soluble brain protein) [17] and constitutes a principal component of Lewy bodies in sporadic PD [45], such a structural alteration may contribute to the accumulation/aggregation of UCH-L1 (and/or mutants thereof) in the diseased state. Thus, there may be a correlation between structural changes within UCH-L1 and PD-associated Lewy body formation. However, further detailed biochemical and biophysical characterization of the I93M UCH-L1 mutant is required to confirm this possibility.

The protein structure is altered only in I93M UCH-L1 and the ligase activity is decreased both in I93M and S18Y UCH-L1s [29]. However, only the hydrolase activity correlates inversely with the risk of PD (Table 2). Therefore, the change in hydrolase activity in both I93M and S18Y UCH-L1 variants may be responsible, in whole or part, for the differences in PD risk observed in the two populations carrying these distinct alleles.

Two other causative genes, *parkin* and α -synuclein, have been linked to familial PD (reviewed in 46). *Parkin* exhibits E3 ubiquitin ligase activity [47,48]. *Parkin*-associated endothelin receptor-like receptor (Pael-R) has been identified as a substrate for *parkin* [49]. *Parkin* is thought to remove misfolded proteins such as Pael-R from the endoplasmic reticulum (ER) and to protect neurons from ER-mediated stress-induced cell death [49]. α -Synuclein, a core component of Lewy bodies [50], is also a substrate for *parkin* and therefore *parkin* may be involved in Lewy body formation as well [51]. It was proposed that UCH-L1 is a neuron-specific ubiquitin hydrolase required to maintain cellular levels of 'free ubiquitin' (i.e., ligatable at the C-terminus) [12]. The decreased hydrolase activity of the I93M UCH-L1 mutant possibly results in reduced levels of free ubiquitin that may adversely affect the normal degradation of Pael-R and α -synuclein. Conversely, the increased hydrolase activity of the S18Y mutant may elevate cellular free ubiquitin levels, resulting in enhanced degradation of Pael-R and α -synuclein. Moreover, the increased hydrolase activity of S18Y UCH-L1 coupled with its decreased ligase activity (which can prevent α -synuclein degradation by K63-linked ubiquitin ligation) [29] may be additive or synergistic with respect to the decreased risk of sporadic PD. These hypotheses may be confirmed in future in vivo studies designed to measure cellular

Table 2
Association between Parkinson's disease and human UCH-L1 mutants

UCH-L1 variant	WT	I93M	S18Y	References
Incidence of Parkinson's disease		↑	↓	[19–24]
Hydrolase activity	(100%)	↓ (45.6%)	↑ (112.6%)	[19, this study]
CD spectra alteration	Normal	↓ (α -Helix)	Normal	
Ubiquitin ligase activity	(100%)	↓	↓↓	[29]

levels of C-terminal-modified and -free ubiquitin in nigral neurons expressing PD-associated UCH-L1 variants.

Oxidative stress is believed to play a role in the pathogenesis of sporadic PD by promoting the generation and accumulation of oxidant-modified proteins that exhibit aberrant properties [46,52]. HNE, a good candidate for an endogenous toxic oxidizing factor, possibly affects the neuronal ubiquitin–proteasome pathway since UCH-L1 is directly modified by HNE in vitro, resulting in a significant decrease in hydrolase activity. This loss of activity could affect the level of free ubiquitin in a manner similar to that of the UCH-L1 mutants, and consequently may affect the risk of PD. Therefore, the disruption of control mechanisms within the ubiquitin–proteasome pathway via changes in UCH-L1 hydrolase activity may represent a common origin for the pathogenesis of both sporadic and familial PD.

Acknowledgments

This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare of Japan, Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, a grant from the Organization for Pharmaceutical Safety and Research, a grant from Japan Science and Technology Cooperation, and a grant from the Japan Society for the Promotion of Science (JSPS) Research Fellowships (to S.A.). Y.-L.W. is a research fellowship of the Japan Foundation for Aging and Health.

References

- [1] K.D. Wilkinson, Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment, *J. Nutr.* 129 (1999) 1933–1936.
- [2] A. Hershko, A. Ciechanover, The ubiquitin system, *Annu. Rev. Biochem.* 67 (1998) 425–479.
- [3] A. Ciechanover, A. Orian, A.L. Schwartz, The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications, *J. Cell Biochem. Suppl.* 34 (2000) 40–51.
- [4] K.D. Wilkinson, Regulation of ubiquitin-dependent processes by deubiquitinating enzymes, *FASEB J.* 11 (1997) 1245–1256.
- [5] K.D. Wilkinson, M. Hochstrasser, The deubiquitinating enzyme, in: J.M. Peters, J.R. Harris, D. Finley (Eds.), *Ubiquitin and the Biology of the Cell*, Plenum Press, New York, 1998, pp. 99–125.
- [6] R.T. Baker, J.W. Tobias, A. Varshavsky, Ubiquitin-specific proteases of *Saccharomyces cerevisiae*. Cloning of UBP2 and UBP3, and functional analysis of the UBP gene family, *J. Biol. Chem.* 267 (1992) 23364–23375.
- [7] M. Hochstrasser, Protein degradation or regulation: Ub the judge, *Cell* 84 (1996) 813–815.
- [8] C.M. Pickart, I.A. Rose, Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin carboxyl-terminal amides, *J. Biol. Chem.* 260 (1985) 7903–7910.
- [9] J.W. Tobias, A. Varshavsky, Cloning and functional analysis of the ubiquitin-specific protease gene UBP1 of *Saccharomyces cerevisiae*, *J. Biol. Chem.* 266 (1991) 12021–12028.
- [10] M.J. Schlesinger, U. Bond, Ubiquitin genes, *Oxf. Surv. Eukaryot Genes* 4 (1987) 77–91.
- [11] C.N. Larsen, J.S. Price, K.D. Wilkinson, Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues, *Biochemistry* 35 (1996) 6735–6744.
- [12] C.N. Larsen, B.A. Krantz, K.D. Wilkinson, Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases, *Biochemistry* 37 (1998) 3358–3368.
- [13] A.N. Mayer, K.D. Wilkinson, Detection, resolution, and nomenclature of multiple ubiquitin carboxyl-terminal esterases from bovine calf thymus, *Biochemistry* 28 (1989) 166–172.
- [14] K.D. Wilkinson, Roles of ubiquitinylation in proteolysis and cellular regulation, *Annu. Rev. Nutr.* 15 (1995) 161–189.
- [15] Y. Osawa, Y.L. Wang, H. Osaka, S. Aoki, K. Wada, Cloning, expression, and mapping of a mouse gene, *Uchl4*, highly homologous to human and mouse *Uchl3*, *Biochem. Biophys. Res. Commun.* 283 (2001) 363–367.
- [16] K.D. Wilkinson, S. Deshpande, C.N. Larsen, Biochem. Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases, *Soc. Trans.* 20 (1992) 631–637.
- [17] K.D. Wilkinson, K.M. Lee, S. Deshpande, P. Duerksen-Hughes, J.M. Boss, J. Pohl, The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase, *Science* 246 (1989) 670–673.
- [18] K. Saigoh, Y.L. Wang, J.G. Suh, T. Yamanishi, Y. Sakai, H. Kiyosawa, T. Harada, N. Ichihara, S. Wakana, T. Kikuchi, K. Wada, Intragenic deletion in the gene encoding ubiquitin carboxyl-terminal hydrolase in *gad* mice, *Nat. Genet.* 23 (1999) 47–51.
- [19] E. Leroy, R. Boyer, G. Auburger, B. Leube, G. Ulm, E. Mezey, G. Harta, M.J. Brownstein, S. Jonnalagada, T. Chernova, A. Dehejia, C. Lavedan, T. Gasser, P.J. Steinbach, K.D. Wilkinson, M.H. Polymeropoulos, The ubiquitin pathway in Parkinson's disease, *Nature* 395 (1998) 451–452.
- [20] Y. Momose, M. Murata, K. Kobayashi, M. Tachikawa, Y. Nakabayashi, I. Kanazawa, T. Toda, Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms, *Ann. Neurol.* 51 (2002) 133–136.
- [21] J. Satoh, Y. Kuroda, A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population, *J. Neurol. Sci.* 189 (2001) 113–117.
- [22] P. Wintermeyer, R. Kruger, W. Kuhn, T. Muller, D. Voitalla, D. Berg, G. Becker, E. Leroy, M. Polymeropoulos, K. Berger, H. Przuntek, L. Schols, J.T. Epplen, O. Riess, Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients, *Neuroreport* 11 (2000) 2079–2082.
- [23] J. Zhang, N. Hattori, E. Leroy, H.R. Morris, S. Kubo, T. Kobayashi, N.W. Wood, M.H. Polymeropoulos, Y. Mizuno, Association between a polymorphism of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease, *Parkinsonism Relat. Disord.* 6 (2000) 195–197.
- [24] D.M. Maraganore, M.J. Farrer, J.A. Hardy, S.J. Lincoln, S.K. McDonnell, W.A. Rocca, Case-control study of the ubiquitin carboxyl-terminal hydrolase L1 gene in Parkinson's disease, *Neurology* 53 (1999) 1858–1860.
- [25] C. Levecque, A. Destee, V. Mouroux, E. Becquet, L. Defebvre, P. Amouyel, M.C. Chartier-Harlin, No genetic association of the ubiquitin carboxyl-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease, *J. Neural Transm.* 108 (2001) 979–984.
- [26] G. Savettieri, E.V. De Marco, D. Civitelli, G. Salemi, G. Nicoletti, G. Annesi, I.C. Ciro Candiano, A. Quattrone, Lack of association between ubiquitin carboxyl-terminal hydrolase L1 gene polymorphism and PD, *Neurology* 57 (2001) 560–561.
- [27] G.D. Mellick, P.A. Silburn, The ubiquitin carboxyl-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease, *Neurosci. Lett.* 293 (2000) 127–130.

- [28] S. Lincoln, J. Vaughan, N. Wood, M. Baker, J. Adamson, K. Gwinn-Hardy, T. Lynch, J. Hardy, M. Farrer, Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease, *Neuroreport* 10 (1999) 427–429.
- [29] Y. Liu, L. Fallon, H.A. Lashuel, Z. Liu, P.T. Lansbury Jr., The UCH-L1 gene encodes two opposing enzymatic activities that affect α -synuclein degradation and Parkinson's disease susceptibility, *Cell* 111 (2002) 209–218.
- [30] L.C. Dang, F.D. Melandri, R.L. Stein, Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes, *Biochemistry* 37 (1998) 1868–1879.
- [31] R.J. Perrin, W.S. Woods, D.F. Clayton, J.M. George, Interaction of human α -synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis, *J. Biol. Chem.* 275 (2000) 34393–34398.
- [32] J.T. Yang, C.S. Wu, H.M. Martinez, Calculation of protein conformation from circular dichroism, *Methods Enzymol.* 130 (1986) 208–269.
- [33] K. Uchida, E.R. Stadtman, Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction, *J. Biol. Chem.* 268 (1993) 6388–6393.
- [34] P.J. Lockhart, L. Hill, T. Chernova, K. Wilkinson, M.J. Farrer, in: *Proceedings of the 32th Annual Meeting Society for Neuroscience*, Orlando, FL, November 2–7, 2002 (Abstr. 887.6), Society for neuroscience, Washington, DC, 2002.
- [35] S.C. Johnston, C.N. Larsen, W.J. Cook, K.D. Wilkinson, C.P. Hill, Crystal structure of a deubiquitinating enzyme human (UCH-L3) at 1.8Å resolution, *EMBO J.* 16 (1997) 3787–3796.
- [36] J.W. Crabb, J. O'Neil, M. Miyagi, K. West, H.F. Hoff, Hydroxynonenal inactivates cathepsin B by forming Michael adducts with active site residues, *Protein Sci.* 11 (2002) 831–840.
- [37] J.N. Keller, K.B. Hanni, W.R. Markesbery, 4-hydroxynonenal increases neuronal susceptibility to oxidative stress, *J. Neurosci. Res.* 58 (1999) 823–830.
- [38] I. Kruman, A.J. Bruce-Keller, D. Bredesen, G. Waeg, M.P. Mattson, Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis, *J. Neurosci.* 17 (1997) 5089–5100.
- [39] A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E.R. Stadtman, Y. Mizuno, Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, *Proc. Natl. Acad. Sci. USA* 93 (1996) 2696–2701.
- [40] R.J. Castellani, G. Perry, S.L. Siedlak, A. Nunomura, S. Shimohama, J. Zhang, T. Montine, L.M. Sayre, M.A. Smith, Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans, *Neurosci. Lett.* 319 (2002) 25–28.
- [41] H. Esterbauer, R.J. Schaur, H. Zollner, Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes, *Free Radic. Biol. Med.* 11 (1991) 81–128.
- [42] A.M. Gioacchini, N. Calonghi, C. Boga, C. Cappadone, L. Masotti, A. Roda, P. Traldi, Determination of 4-hydroxy-2-nonenal at cellular levels by means of electrospray mass spectrometry, *Rapid. Commun. Mass Spectrom* 13 (1999) 1573–1579.
- [43] M.L. Selley, (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease, *Free Radic. Biol. Med.* 25 (1998) 169–174.
- [44] J.F. Doran, P. Jackson, P.A. Kynoch, R.J. Thompson, Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution two-dimensional electrophoresis, *J. Neurochem.* 40 (1983) 1542–1547.
- [45] J. Lowe, H. McDermott, M. Landon, R.J. Mayer, K.D. Wilkinson, Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases, *J. Pathol.* 161 (1990) 153–160.
- [46] M.M. Mouradian, Recent advances in the genetics and pathogenesis of Parkinson disease, *Neurology* 58 (2002) 179–185.
- [47] H. Shimura, N. Hattori, S. Kubo, Y. Mizuno, S. Asakawa, S. Minoshima, N. Shimizu, K. Iwai, T. Chiba, K. Tanaka, T. Suzuki, Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase, *Nat. Genet.* 25 (2000) 302–305.
- [48] Y. Zhang, J. Gao, K.K. Chung, H. Huang, V.L. Dawson, T.M. Dawson, Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1, *Proc. Natl. Acad. Sci. USA* 97 (2000) 13354–13359.
- [49] Y. Imai, M. Soda, H. Inoue, N. Hattori, Y. Mizuno, R. Takahashi, An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin, *Cell* 105 (2001) 891–902.
- [50] M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, M. Goedert, α -Synuclein in Lewy bodies, *Nature* 388 (1997) 839–840.
- [51] H. Shimura, N. Hattori, S. Kubo, M. Yoshikawa, T. Kitada, H. Matsumine, S. Asakawa, S. Minoshima, Y. Yamamura, N. Shimizu, Y. Mizuno, Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients, *Ann. Neurol.* 45 (1999) 668–672.
- [52] E.R. Stadtman, R.L. Levine, Protein oxidation, *Ann. N. Y. Acad. Sci.* 899 (2000) 191–208.

Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron

Hitoshi Osaka^{1,2,†,‡}, Yu-Lai Wang^{1,†}, Koji Takada³, Shuichi Takizawa^{1,4}, Rieko Setsuie^{1,5}, Hang Li¹, Yae Sato^{1,5}, Kaori Nishikawa¹, Ying-Jie Sun¹, Mikako Sakurai^{1,5}, Takayuki Harada¹, Yoko Hara^{1,6}, Ichiro Kimura⁶, Shigeru Chiba⁴, Kazuhiko Namikawa⁷, Hiroshi Kiyama⁷, Mami Noda⁵, Shunsuke Aoki¹ and Keiji Wada^{1,*}

¹Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8502, Japan, ²Information and Cellular function, PRESTO, Japan Science and Technology Corporation (JST), Kawaguchi, Saitama 332-0012, Japan, ³Department of Biochemistry 1, Jikei University School of Medicine, Minato-ku, Tokyo, 105-8461, Japan, ⁴Department of Psychiatry and Neurology, Asahikawa Medical College, Asahikawa, 078-8510, Japan, ⁵Laboratory of Pathophysiology, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka, 812-8582, Japan, ⁶Department of Basic Human Science, School of Human Science, Waseda University, Tokorozawa, 359-1192, Japan and ⁷Department of Anatomy and Neurobiology, Graduate School of Medicine, Osaka City University, Abeno-ku, Osaka, 545-8585, Japan

Received March 13, 2003; Revised June 6, 2003; Accepted June 17, 2003

Mammalian neuronal cells abundantly express a deubiquitylating enzyme, ubiquitin carboxy-terminal hydrolase 1 (UCH L1). Mutations in UCH L1 are linked to Parkinson's disease as well as gracile axonal dystrophy (*gad*) in mice. In contrast to the UCH L3 isozyme that is universally expressed in all tissues, UCH L1 is expressed exclusively in neurons and testis/ovary. We found that UCH L1 associates and colocalizes with monoubiquitin and elongates ubiquitin half-life. The *gad* mouse, in which the function of UCH L1 is lost, exhibited a reduced level of monoubiquitin in neurons. In contrast, overexpression of UCH L1 caused an increase in the level of ubiquitin in both cultured cells and mice. These data suggest that UCH L1, with avidity and affinity for ubiquitin, insures ubiquitin stability within neurons. This study is the first to show the function of UCH L1 *in vivo*.

INTRODUCTION

The small 76-amino acid protein ubiquitin (Ub) plays a critical role in many cellular processes, including the cell cycle, cell proliferation, development, apoptosis, signal transduction and membrane protein internalization (1). Moreover, Ub and/or Ub-containing protein aggregates are hallmarks of various neurodegenerative conditions (2). Fundamentally, monoubiquitylation constitutes a sorting signal for membrane proteins to the endosome–lysosomal pathway while polyubiquitylated proteins (covalently linked to Lys48 of Ub) are targeted to the 26S proteasome for degradation. At least three classes of enzymes are engaged in the ubiquitylation processes, namely the

E1 (Ub-activating), E2 (Ub-conjugating) and E3 (Ub ligase) enzymes (1). Ubiquitylation also controls the sorting and localization of certain proteins in a reversible manner, much as phosphorylation modulates changes in the structure, activity and the localization of the target proteins. As such, deubiquitylating enzymes (DUBs) act analogously to phosphatases that function in phosphorylation processes (3).

DUBs are subdivided into Ub C-terminal hydrolases (UCHs) and Ub-specific proteases (UBPs). Both classes are thiol proteases that hydrolyze the isopeptide bond between the substrate and the C-terminal Gly76 of Ub. UCHs can hydrolyze bonds between Ub and small adducts or unfolded polypeptides *in vitro* (4). UCHs also can cleave Ub gene products very slowly

*To whom correspondence should be addressed at: Department of Degenerative Neurological Diseases, National Institute of Neuroscience, NCNP, Kodaira, Tokyo, 187-8502, Japan. Tel: +81 423461715; Fax: +81 423461745; Email: wada@ncnp.go.jp

[†]The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.

[‡]Present address:

Division of Neurology, Clinical Research Institute, Kanagawa Children's Medical Center, Yokohama, 232-8555, Japan.

in vitro, either tandemly conjugated Ub monomers (UbB, UbC) or Ub fused to small ribosomal proteins (L40, S27a), to yield free Ub or ribosomal proteins, respectively (4,5). Yeast expresses one UCH (YUH1) and 16 UBPs (Ubp1–16). Two YUH1 homologs, UCH L1 and UCH L3, have been characterized in mammals (6,7). UCH L1 and UCH L3 are both small proteins of ~220 amino acids that share more than 40% amino acid sequence identity. However, the distribution of these isozymes is quite distinct in that UCH L3 is expressed ubiquitously while UCH L1 is selectively expressed in neuronal cells and the testis/ovary (6,7).

UCH L1 is one of the most abundant proteins in the brain (1–5% of total soluble protein) and immunohistological experiments demonstrate that it is localized exclusively to neurons (6). Although the role of UCH L1 *in vivo* remains unclear, its abundance and specificity for neurons predict a role in neuronal cell function/dysfunction. Similar to Ub, UCH L1 is a constituent of cellular aggregates that are indicative of neurodegenerative disease such as Lewy bodies in Parkinson's disease (PD) (8). Indeed, an isoleucine-to-methionine substitution at amino acid 93 of UCH L1 was reported in a family with a dominant form of PD (9). We found that a *Uch 11* gene deletion in mice causes gracile axonal dystrophy (*gad*), a recessive neurodegenerative disease (10,11). These two examples of neurological disorders in both humans and mice prompted us to investigate the function of UCH L1 in neuronal cells.

We show here that the *gad* mouse is analogous to a *Uch 11* null mutant. Using this mouse and *Uch 11* transgenic mice, we report a novel *in vivo* role for UCH L1 in Ub homeostasis that was unexpected from previous *in vitro* work (12,13). Our data show that UCH L1 associates with Ub in neuronal cells and suggest that this association is important for the maintenance of mono-Ub levels in neurons. UCH L1 effectively upregulates Ub levels at the post-translational level, and this upregulation is probably based on the inhibition of Ub degradation by UCH L1.

RESULTS

UCH L1 is undetectable in the *gad* mouse

The *gad* mouse carries a deletion of a genomic fragment including exons 7 and 8 of *Uchl1* (10). Given such a substantial deletion, the protein encoded by the *gad* allele most likely lacks the core structure of UCH L1, thus predicating its instability [wild-type mouse UCH L1 was modeled using the crystal structure of human UCH L3 (14) as a template; see Fig. 1A]. Immunoblotting using polyclonal antibody to UCH L1 failed to detect UCH L1 in either soluble (10) or insoluble brain lysates from the *gad* mouse (data not shown). Thus, the *gad* mouse is analogous to a *Uch 11* null mutant. Next, we examined whether UCH L3, another UCH in the brain, is upregulated by this mutation. The *gad* mouse showed comparable levels of UCH L3 mRNA and protein (Fig. 1B). Therefore, the phenotype in the mouse does not appear to be modified by compensatory UCH L3 up-regulation. We then employed this mutant mouse to characterize UCH L1 substrates or associated proteins *in vivo*.

UCH L1 associates with Ub

There should be physiological substrates for UCH L1 that accumulate in the *gad* mouse. To facilitate isolation of such UCH L1 substrates or associated proteins, mutant UCH L1^{C90S} was purified from an *E. coli* expression system. UCH L1^{C90S} lacks Ub carboxy-terminal hydrolase activity but retains the ability to associate with Ub (4) (Table 1). As such, UCH L1^{C90S} represented an ideal tool for the purpose of binding to and isolating *in vivo* protein substrates or associates for UCH L1. His-UCH L1^{C90S} and Ni-Sepharose resin were employed in a pull-down assay using soluble brain lysates from wild-type and *gad* mice. Eluates from the resin were subjected to SDS-PAGE and SELDI (surface-enhanced laser desorption/ionization) time-of-flight (TOF) analysis. Relative to wild-type lysates, consistently elevated levels of proteins were not detected in the *gad* mice brains including putative substrates of poly-Ub. Rather, the level of an ~8 kDa protein was consistently lower in *gad* mice lysates (Fig. 1C; left panel; band intensity of *gad* to wild-type is 0.80 ± 0.09 , $n = 3$). In both lysates, this protein band was immunoreactive with an antibody to Ub (Fig. 1C; right panel). In-gel digestion of this band followed by tandem liquid chromatography/mass spectrometry produced two peptide sequences—TLSYNIQKESTLHLVLR and TITLEVEPSDTIENVK—that were 100% identical to sequences within mouse Ub. In another pull-down assay, His-Ub pulled down a band corresponding to UCH L1 (Fig. 1D). SELDI analysis showed identical mass peak patterns for the Ub band from wild-type and *gad* mice (Fig. 1E) with a principal mass peak at 8560.8 *m/z*, consistent with the *m/z* expected for free mono-Ub (8564.8). Wild-type and *gad* mouse brain lysates were then subjected to gel filtration chromatography and immunoblotted with anti-UCH L1 or anti-Ub. In the fractions from the wild-type mouse, mono-Ub eluted over the range of ~10–50 kDa, overlapping significantly with the elution of UCH L1 (Fig. 1F). In fractions from the *gad* mouse, however, mono-Ub eluted exclusively at ~10–14 kDa. These data suggest that UCH L1 associates with mono-Ub.

Loss of UCH L1 decreases the level of Ub in neuron

The expression and localization of UCH L1 and mono-Ub in the mouse nerve system were examined. The nervous system is consisted of two types of cells, nerve cells (neurons) and glia (astrocytes, oligodendrocytes/schwann cells, microglia, ependymal cells). Immunofluorescence microscopy shows UCH L1 co-expresses with a neuron marker, neurofilament (NF), but not with an oligodendrocytes marker, proteolipid protein (PLP), and an astrocytes marker, glial fibrillary acidic protein (GFAP), thus supporting the neuron-specific expression of UCH L1 (6) (Fig. 2A). Then double immunofluorescence labeling was performed in neural tissue using UCH L1 antibody and polyclonal Ub antibody that predominantly recognizes free Ub (Sigma) (15). It was found that immunoreactivities to anti-UCH L1 and anti-Ub colocalized within the neuron (Fig. 2B, upper panel). Moreover, Ub immunoreactivity was reduced in neurons in *gad* mice (Fig. 2B, lower panel). In the peripheral nerve, neuronal axons are enwrapped by myelin of glial schwann cells that are immunoreactive to myelin basic protein antibody (Fig. 2C, right and left panels). Immunohistochemistry




Figure 1. UCH L1 associates with ubiquitin. (A) Mouse UCH L1 was modeled after the crystal structure of human UCH L3 (14) using Insight II/Modeler (SGI). Secondary structures of the peptides deleted in the gracile axonal dystrophy (*gad*) mouse are shown in yellow. (B, upper panel) Quantitative RT-PCR for *Uch 13* was performed using total RNA from wild-type and *gad* (*gad/gad*) cerebra ($n = 3$ each). Mean values are shown with SEM. β -Actin (open bar) or GAPDH (solid bar) were used as internal controls. (B, lower panel) Soluble fractions (20 μ g) of wild-type (+/+), the *gad* (*g/g*) and *Uch 13*^{*43-7*}/*Uch 13*^{*43-7*} (*13*⁻/*13*⁻) (38) mouse brains were subjected to SDS-PAGE and immunoblotted with anti-UCH L1. (C) Eluates from pull-down assays using His-UCH L1^{C90S} and brain lysate were subjected to SDS-PAGE, stained with Coomassie brilliant blue (left panel) and the band intensities to mono-Ub were compared. Eluates were also immunoblotted with monoclonal anti-Ub (right panel; Chemicon). Arrow shows the bands corresponding to mono-Ub. Asterisk shows the non-specific band that is co-purified during UCH L1 purification. (D) Eluates from pull-down assays using His-Ub and brain lysate were subjected to SDS-PAGE and immunoblotted with anti-UCH L1. The arrow shows the band corresponding to UCH L1. (E) Eluates from pull-down assays using His-UCH L1^{C90S} and brain lysate were desalted with a C₁₈ zip tip column and subjected to SELDI analysis. An *m/z* range near that expected for Ub ($m/z = 8562$) is presented. (F) Selected gel filtration chromatography fractions from wild-type brain lysates (upper and middle panels) and *gad* mice brain lysates (lower panel) were subjected to SDS-PAGE and immunoblotted with anti-UCH L1 (upper panel) or anti-Ub (middle and lower panels). The arrowhead and arrow correspond to the peak ovalbumin (43 kDa) and ribonuclease A (14 kDa) fractions, respectively.

Table 1. Kinetic parameters for hydrolysis of ubiquitin-7 amid-4 methylcoumarin (Ub-AMC) by mouse UCH L1 and inhibition by Ub

Enzyme	K_m (μM)	k_{cat} (s^{-1})	$10^6 \times k_{\text{cat}}/K_m$ ($\text{M}^{-1} \text{s}^{-1}$)	K_i (μM)
UCH L1 ^{WT}	0.16	0.02	0.13	3.3
UCH L1 ^{D30K}	—	0	0	[0.28] ^b
UCH L1 ^{C90S}	—	0 ^a	0	[0.86] ^b

Steady-state kinetic parameters were determined at 25°C in assay buffer.

The mean values of three independent experiments are shown.

^aNo products were observed after 30 min with 5 mM enzyme.

Inhibitions were not assayed due to the lack of activity to substrates.

^b[Ratio of pulled down Ub to WT].

shows Ub immunoreactivity is decreased in neurons but not at glial schwann cells (Fig. 2D, middle panel).

Subsequently, cytosolic fractions of various nervous tissues that include both neuron and glia were subjected to SDS-PAGE and immunoblotted with a monoclonal Ub antibody that recognizes both free and conjugated Ub in denatured states (Chemicon) (15). The principal band corresponded to free mono-Ub, the intensity of which was reduced in *gad* mouse tissues (Fig. 3A, right panel) suggesting that mono-Ub is decreased in the absence of UCH L1 in the nervous system. A longer exposure or autoclaving the membrane enhanced the bands corresponding to Ub conjugates where no significant differences between wild-type and *gad* mice were observed (data not shown). Then mono-Ub levels in the nervous systems in <2-week-old wild-type and *gad* mice were measured by the radioimmunoassay (13). The inhibition rates for the ¹²⁵I-mono-Ub bound to antibody US-1 by brain lysates were compared with the standard curve generated by unlabeled mono-Ub (13). US-1 is specific antibody for free mono-Ub (13). Reduced levels of free mono-Ub (~20–30% reduction) were observed in each of the *gad* mouse tissues even at this early age (Fig. 3B; pathology in these mice was apparent only after >6 weeks). Immunoblotting and radioimmunoassay use cell lysates that contain both neuron and glia, which appears to be the reason for the apparent discrepancy between the large difference in Ub immunohistochemistry in neurons and relatively smaller differences in mono-Ub levels in immunoblotting/radioimmunoassay.

These data show that Ub is associated with UCH L1 in neurons. Absence of UCH L1 reduces the mono-Ub level in neurons, which causes the reduction of overall mono-Ub level in the nervous system.

UCH L1 overexpression increases Ub levels

The effect of UCH L1 overexpression on Ub levels was examined in both cultured cells and transgenic mice. Adenovirus vectors expressing UCH L1 (adeno-*Uch 11*) or β -galactosidase (adeno- β -*gal*) were transfected into mouse embryonic fibroblasts (MEF) cells that do not express UCH L1. After transfection, UCH L1 was induced by Cre recombinase. Reactivity to anti-Ub exist at both nucleus and cytosol in adeno β -*gal* transfected and non-transfected MEF cells (Fig. 4B and C). Surprisingly, MEF cells transfected with adeno-*Uch 11* express UCH L1 dominantly at cytosol, where immunoreactivities to anti-Ub and anti-UCH L1




Figure 2. Loss of UCH L1 decreases ubiquitin immunoreactivity. Confocal laser scanning microscopy of mouse brain stem sections (A, B), sciatic nerve (C; left and middle panels) and electron microscopy for sciatic nerve (C; right panels) from 12-week-old wild-type or *gad* mice. (A) Immunohistochemistry to coronal sections at the brain stem, pons (fourth ventricle situates at the upper edges). Antibodies to a neuron marker, neurofilament (NF; left panel, green) and a glial oligodendrocytes marker, proteolipid protein (PLP; middle panel, green) and a glial astrocytes marker, glial fibrillary acidic protein (GFAP; right panel, green) were used for co-immunostaining with anti-UCH L1 (red). Immunoreactivity to anti-NF partially merges with that to anti-UCH L1. NFs exist at neuritis but not at a cell body of a neuron, whereas UCH L1 is expressed at both neuritis and cell bodies. Immunoreactivities to anti-PLP and anti-GFAP do not co-localize with that to anti-UCH L1. Scale bars, 40 μm . (B) Sections at neuronal nucleus in the pons from wild-type (upper panel) and *gad* mice (lower panel) were stained with anti-UCH L1 (green) and polyclonal anti-Ub (red; Sigma) on the same slide. Immunoreactivity to anti-UCH L1 is merged with that to anti-Ub. Moreover, immunoreactivity to anti-Ub is decreased in the *gad* mice that showed no reactivity to anti-UCH L1. Scale bars, 10 μm . Insets are images at four times higher magnification. (C) Sciatic nerve is composed of inner neuronal axon and outer myelin that is immunoreactive to anti-myelin basic protein (MBP, the marker of glial schwann cells, left panels). Immunoreactivity to anti-Ub in the neuronal axon (inside of dashed line) is decreased in the *gad* mouse, whereas the immunoreactivity to anti-Ub in glial myelin (outside the dashed line) is comparable between wild-type and *gad* mice. Electron microscopic images show fine structures of myelin and axon that are similar between wild-type and *gad* mouse in this 12 weeks of age (right panel). Scale bars, 10 μm .

are completely merged (Fig. 4A). Then the levels of Ub were compared by immunoblotting. The level of free mono-Ub as well as ubiquitylated proteins increased relative to the β -*gal* control at 24h after UCH L1 induction (Fig. 4D; band intensity ratio of